Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Komrokji, R., Lancet, J., Kantarjian, H. M., Gu, L., Zhang, Y., Tan, A., … Daver, N. G. (2023). Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of Clinical Oncology, 41(15), 2815–2826. https://doi.org/10.1200/jco.22.01794
Authors:
David A. Sallman
Monzr M. Al Malki
Adam S. Asch
Eunice S. Wang
Joseph G. Jurcic
Terrence Bradley
Ian W. Flinn
Daniel A. Pollyea
Suman Kambhampati
Tiffany Tanaka
Joshua F. Zeidner
Guillermo Garcia‐Manero
Deepa Jeyakumar
Rami S. Komrokji
Jeffrey E. Lancet
Hagop M. Kantarjian
Lin Gu
Yajia Zhang
Anderson Tan
Mark P. Chao
Carol O’Hear
Giridharan Ramsingh
Indu Lal
Paresh Vyas
Naval Daver
Affiliated Authors:
Joseph G. Jurcic
Publication Type:
Article
Unique ID:
10.1200/jco.22.01794
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: